Health News Releases

December 21, 10:30

Parse Biosciences and Codebreaker Labs Partner to Apply Whole Transcriptome Single Cell Profiling and Causal Genomics at Scale

Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced a collaboration with Codebreaker Labs to develop and validate a breakthrough platfo

December 19, 16:50

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation

December 18, 17:09

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54379786&newsitemid=20251218728397&lan=en-US&anchor=TSE%3A4

December 18, 15:00

Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform

Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On

December 18, 11:45

GE HealthCare and Indonesia’s Ministry of Health to expand access to quality care through the provision of 300+ advanced CT scanners

GE HealthCare (Nasdaq: GEHC) today announced it will supply more than 300 CT (computed tomography) scanners under Indonesia’s Strengthening Indonesia’s Health Referral Network (SIHREN) program to deli

December 18, 08:53

Sinovac: Antigua Court Makes Interim Order Giving Board Control of the Company until the Trial of the Disputed 2025 Shareholder Meeting

Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced that the Antigua High Court has ordered that the directors Mr. S

December 17, 15:45

New Published Data Confirms Nemluvio® (Nemolizumab) Can Rapidly Relieve Itch and Improve Sleep in as Early as Two Days in Both Atopic Dermatitis and Prurigo Nodularis

Galderma (SIX: GALD), the pure-play dermatology category leader, today released new clinical data confirming nemolizumab’s rapid onset of action on itch and sleep, with significant improvements observ

December 16, 15:30

Novotech Issues White Paper to Help Sponsors Strengthen Early-Phase Oncology Strategy and Execution

Novotech, a leading global full-service clinical research organization (CRO) and scientific advisory company, has released a new white paper, Early-Phase Oncology - Clinical Research Landscape and CRO

December 14, 14:05

Tahoe Therapeutics Selects Parse Biosciences’ GigaLab to Generate 300 Million Single Cell Profiles for Large-Scale Perturbation Atlas

Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced that Tahoe Therapeutics has selected Parse’s GigaLab to generate data for its upcomin

December 12, 10:00

Biocytogen Completes STAR Market IPO, Becoming the First “H+A” Global Drug Innovator

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen,” SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing on t

December 11, 17:50

Polpharma Biologics and Libbs Farmacêutica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the signing of a landmark licensing agreement with th

December 11, 16:35

Galderma Announces First Patient Enrollment in Study to Assess Nemolizumab in Adults With Chronic Pruritus of Unknown Origin

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the first patient enrollment for its phase II study investigating the efficacy and safety of nemolizumab in treating pa

December 11, 15:40

Cleveland Clinic Neurological Institute and Baszucki Group Team Up to Advance Landmark Brain Study with Metabolic Health Markers

Baszucki Group today announced an expanded commitment to the landmark Cleveland Clinic Brain Study (https://my.clevelandclinic.org/departments/neurological/research-innovations/brain-study). Launched

December 10, 15:35

SoluPet Inc. (SoluPet) Announces Strategic Partnership with CHC Healthcare Group (CHC) to Advance Canine Cognitive Health in Asia

SoluPet, the data and science-driven pet cognitive health company developing advanced cognitive-aging support for senior dogs, today announced a strategic partnership with CHC, one of Asia’s largest p

December 10, 14:10

BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

BeOne Medicines Ltd. (https://beonemedicines.com/) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) innova

December 09, 16:40

IBMI SNQ and ICHOM Forms Strategic Partnership in Asia, Advancing Patient-centered Healthcare in the Region

The Symbol of National Quality (SNQ), initiated by Taiwan’s Institute for Biotechnology and Medicine Industry (IBMI), has partnered with the International Consortium for Health Outcomes Measurement (I

December 09, 15:20

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

BeOne Medicines Ltd. (https://beonemedicines.com/) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 i

December 09, 15:00

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results o

December 08, 15:12

Galderma Welcomes Increased Equity Investment From L’Oréal

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake

December 05, 17:15

IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance o

December 05, 15:40

Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its certification under the EU

December 05, 14:15

Parse Biosciences Launches Evercode Whole Blood Fixation

Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of Evercode™ Whole Blood Fixation, a new kit that enables immediate fixati

December 05, 11:20

University of Maryland Launches Innovative Clinician Training Program in Ketogenic Metabolic Therapy for Mental Health

Baszucki Group today announced a partnership with University of Maryland School of Medicine for an innovative training initiative that will build capacity for delivering ketogenic metabolic therapy in

December 05, 11:00

Famenity's Brain Factor-7® Gains Global Momentum as Clinically Validated Ingredient for Cognitive Health

Famenity Co., Ltd. (https://famenity.com/home-en/), a South Korean research and development company specializing in functional ingredients for health supplements, said that its Brain Factor-7® (BF-7®)

December 04, 15:09

Galderma Secures ‘BBB’ Credit Rating With Positive Outlook from S&P Global Ratings

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that S&P Global Ratings (S&P) has assigned the company a ‘BBB’ long-term issuer credit rating with a positive o

News by Region

News by Industry